New treatment for inflammation linked to epilepsy and Alzheimer's disease
Development of a novel anti-neuroinflammatory experimental therapeutic for epilepsy and Alzheimer's risk
This study is exploring a new treatment that could help reduce inflammation in the brain for people with epilepsy and Alzheimer's disease, using a special molecule called MW189 to potentially improve their symptoms and overall brain health.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Immunochem Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Newton, United States) |
| Project ID | NIH-11256668 on NIH RePORTER |
What this research studies
This research focuses on developing a new therapeutic approach to reduce neuroinflammation associated with epilepsy and Alzheimer's disease. It aims to target the overproduction of proinflammatory cytokines, which contribute to cognitive decline and neurological damage in these conditions. By investigating a novel small molecule, MW189, the research seeks to provide a potential treatment option for patients suffering from these age-related disorders. The study will involve understanding the underlying mechanisms of inflammation and how they relate to both epilepsy and Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are elderly individuals with a history of epilepsy or those at risk for Alzheimer's disease.
Not a fit: Patients who are not elderly or do not have a history of epilepsy or Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that alleviates symptoms and slows the progression of Alzheimer's disease and epilepsy.
How similar studies have performed: Previous research has shown promise in targeting neuroinflammation for treating neurological disorders, suggesting that this approach could be effective.
Where this research is happening
Newton, United States
- Immunochem Therapeutics, LLC — Newton, United States (Active)
Researchers
- Principal investigator: Shifrin, Victor — Immunochem Therapeutics, LLC
- Study coordinator: Shifrin, Victor
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.